BRIEF-Galapagos And Adaptimmune Sign Clinical Collaboration Agreement With An Option To Exclusively License Adaptimmune’s Uza-Cel In Head & Neck Cancer And Potential Future Solid Tumor Indications
Adaptimmune Therapeutics PLC Sponsored ADR ADAP | 0.81 0.81 | -1.68% 0.00% Pre |
Galapagos NV Sponsored ADR GLPG | 30.24 30.24 | -2.61% 0.00% Pre |
Dow Jones Industrial Average DJI | 42924.89 | -0.02% |
S&P 500 index SPX | 5851.20 | -0.05% |
NASDAQ IXIC | 18573.13 | +0.18% |
May 30 (Reuters) - Adaptimmune Therapeutics PLC ADAP.O:
REG-GALAPAGOS AND ADAPTIMMUNE SIGN CLINICAL COLLABORATION AGREEMENT WITH AN OPTION TO EXCLUSIVELY LICENSE ADAPTIMMUNE’S TCR T-CELL THERAPY CANDIDATE, UZA-CEL, IN HEAD & NECK CANCER AND POTENTIAL FUTURE SOLID TUMOR INDICATIONS
GALAPAGOS NV: ADAPTIMMUNE TO RECEIVE INITIAL PAYMENTS OF $100 MILLION
GALAPAGOS NV: ADAPTIMMUNE TO RECEIVE ADDITIONAL DEVELOPMENT AND SALES MILESTONE PAYMENTS OF UP TO A MAXIMUM OF $465 MILLION
GALAPAGOS NV: GALAPAGOS HAS BEEN GRANTED AN OPTION TO EXCLUSIVELY LICENSE UZA-CEL FOR GLOBAL DEVELOPMENT AND COMMERCIALIZATION IN HEAD & NECK CANCER
GALAPAGOS NV-GRANTED OPTION TO EXCLUSIVELY LICENSE UZA-CEL FOR GLOBAL DEVELOPMENT,COMMERCIALIZATION IN POTENTIAL FUTURE SOLID TUMOR CANCER INDICATIONS
Source text for Eikon: ID:nGNE82GRm0
Further company coverage: ADAP.O
((Reutersbriefs@thomsonreuters.com;))
